Welcome to CDC stacks |
Stacks Logo
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
Help
Clear All Simple Search
Advanced Search
Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years
Filetype[HTML]
View this content


This is an HTML document so it cannot be previewed.
To open, click the "View" button.
Details:
  • Alternative Title:
    MMWR. Morbidity and mortality weekly report
  • Description:
    Herpes zoster vaccine (Zostavax, Merck & Co., Inc.) was licensed and recommended in 2006 for prevention of herpes zoster among adults aged 60 years and older. In March 2011, the Food and Drug Administration (FDA) approved the use of Zostavax in adults aged 50 through 59 years. In June 2011, the Advisory Committee on Immunization Practices (ACIP) declined to recommend the vaccine for adults aged 50 through 59 years and reaffirmed its current recommendation that herpes zoster vaccine be routinely recommended for adults aged 60 years and older.

  • Subject:
  • Pubmed ID:
    22071592
  • Document Type:
    Journal Article
  • Collection(s):
    Guidelines and Recommendations
  • Main Document Checksum:
  • Supporting Files:
    No Additional Files
No Related Documents.
You May Also Like:
  1. Update on recommendations for use of herpes zoster vaccine
    Personal Author:
    Hales, Craig M.; Harpaz, Rafael; Ortega-Sanchez, Ismael; Bialek, Stephanie R.;
    Corporate Authors:
    United States. Advisory Committee on Immunization Practices.. National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases..
    Published Date:
    August 22, 2014
    Series:
    MMWR. Morbidity and mortality weekly report, Vol. 63, no. 33, p. 729-31
    Description:
    Herpes zoster vaccine (Zostavax [Merck & Co., Inc.]) was licensed in 2006 and recommended by the Advisory Committee on Immunization Practices (ACIP) in 2008 for prevention of herpes zoster (shingles) and its complications among adults aged ≥60 year...
    Status:
    current
    File Type:
    Filetype[PDF - 195.85 KB]
  2. Update on Recommendations for Use of Herpes Zoster Vaccine
    Personal Author:
    Hales, Craig M.; Harpaz, Rafael; Ortega-Sanchez, Ismael; Bialek, Stephanie R.;
    Corporate Authors:
    United States. Advisory Committee on Immunization Practices.
    Published Date:
    Aug 22 2014
    Source:
    MMWR Morb Mortal Wkly Rep. 2014; 63(33):729-731.
    Description:
    Herpes zoster vaccine (Zostavax [Merck & Co., Inc.]) was licensed in 2006 and recommended by the Advisory Committee on Immunization Practices (ACIP) in 2008 for prevention of herpes zoster (shingles) and its complications among adults aged ≥60 year...
    File Type:
    Filetype[PDF - 109.32 KB]
  3. Use of Herpes zoster vaccine (HZV) in older adults : introduction
    Personal Author:
    Duchin, Jeffrey S.
    Corporate Authors:
    United States. Advisory Committee on Immunization Practices. Herpes Zoster Work Group.. National Center for Immunization and Respiratory Diseases (U.S.). Division of Viral Diseases..
    Conference Authors:
    United States. Advisory Committee on Immunization Practices. Meeting (2013 October 23-24 : Atlanta, GA)
    Published Date:
    October 23, 2013
    Series:
    ACIP meeting Herpes Zoster Vaccine
    File Type:
    Filetype[PDF - 122.54 KB]
  4. Update on post-licensure safety monitoring of recombinant zoster vaccine (RZV, Shingrix)
    Personal Author:
    Shimabukuro, Tom T.
    Corporate Authors:
    National Center for Emerging and Zoonotic Infectious Diseases (U.S.). Immunization Safety Office.
    Conference Authors:
    United States. Advisory Committee on Immunization Practices. Meeting (2019 February 27-28 : Atlanta, GA)
    Published Date:
    February 28, 2019
    Series:
    ACIP meeting Herpes Zoster Vaccine
    Description:
    Zoster-2-Shimabukuro-508.pdf
    File Type:
    Filetype[PDF - 2.25 MB]
  5. Primary Care Physicians’ Experience with Zoster Vaccine Live (ZVL) and Awareness and Attitudes Regarding the New Recombinant Zoster Vaccine (RZV)
    Personal Author:
    Hurley, Laura P.; Allison, Mandy A.; Dooling, Kathleen L.; O’Leary, Sean T.; Crane, Lori A.; Brtnikova, Michaela; Beaty, Brenda L.; Allen, Jessica A.; Guo, Angela; Lindley, Megan C.; Kempe, Allison;
    Published Date:
    October 26 2018
    Source:
    Vaccine. 36(48):7408-7414
    Description:
    Background:The Advisory Committee on Immunization Practices (ACIP) has routinely recommended zoster vaccine live (ZVL) for adults ≥60 since 2008; only 33% of eligible adults received it by 2016. A recombinant zoster vaccine (RZV) was licensed in 20...
    File Type:
    Filetype[PDF - 440.04 KB]